Trial Outcomes & Findings for Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder (NCT NCT01694667)

NCT ID: NCT01694667

Last Updated: 2020-08-31

Results Overview

The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The hyperactivity subscale is comprised of 16 items. The outcome measure is the change from baseline to 6 weeks. The total score ranges from 0 to 48.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

57 participants

Primary outcome timeframe

Baseline, 6 weeks (3 week value to be collected)

Results posted on

2020-08-31

Participant Flow

Recruitment was limited to children between the ages of 5 and 8 with ASD and some verbal ability. E-mail invitations were sent to the 863 registered IAN members who met the above criteria and had given prior consent to be contacted about research opportunities between September 18, 2012 and October 31, 2012.

During the six-week recruitment period, 118 families expressed interest and completed the on-line screening form. Fifty-seven children from 28 states were deemed eligible and randomly assigned to study treatment.

Participant milestones

Participant milestones
Measure
Omega-3 Fatty Acids
Omega-3 fatty acids will be delivered in orange-flavored pudding packets and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA). Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA). 29 participants allocated to this group.
Placebo
Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA). 28 participants allocated to this group.
Overall Study
STARTED
29
28
Overall Study
COMPLETED
29
28
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Total
n=57 Participants
Total of all reporting groups
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=39 Participants
1 Participants
n=41 Participants
3 Participants
n=35 Participants
Age, Continuous
88.2 months
STANDARD_DEVIATION 12.3 • n=39 Participants
85.0 months
STANDARD_DEVIATION 13.2 • n=41 Participants
86.6 months
STANDARD_DEVIATION 12.7 • n=35 Participants
Sex: Female, Male
Female
3 Participants
n=39 Participants
4 Participants
n=41 Participants
7 Participants
n=35 Participants
Sex: Female, Male
Male
26 Participants
n=39 Participants
24 Participants
n=41 Participants
50 Participants
n=35 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=39 Participants
0 Participants
n=41 Participants
1 Participants
n=35 Participants
Race (NIH/OMB)
Asian
1 Participants
n=39 Participants
1 Participants
n=41 Participants
2 Participants
n=35 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=39 Participants
3 Participants
n=41 Participants
4 Participants
n=35 Participants
Race (NIH/OMB)
White
24 Participants
n=39 Participants
23 Participants
n=41 Participants
47 Participants
n=35 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
ABC-Hyperactivity
28.4 units on a scale
STANDARD_DEVIATION 8.4 • n=39 Participants
28.1 units on a scale
STANDARD_DEVIATION 7.6 • n=41 Participants
28.2 units on a scale
STANDARD_DEVIATION 8.0 • n=35 Participants
ABC-Irritability
20.0 units on a scale
STANDARD_DEVIATION 8.9 • n=39 Participants
16.8 units on a scale
STANDARD_DEVIATION 8.3 • n=41 Participants
18.4 units on a scale
STANDARD_DEVIATION 8.7 • n=35 Participants
ABC-Stereotypy
8.0 units on a scale
STANDARD_DEVIATION 6.0 • n=39 Participants
5.4 units on a scale
STANDARD_DEVIATION 4.7 • n=41 Participants
6.7 units on a scale
STANDARD_DEVIATION 5.5 • n=35 Participants
ABC-Lethargy
12.2 units on a scale
STANDARD_DEVIATION 8.8 • n=39 Participants
8.8 units on a scale
STANDARD_DEVIATION 4.2 • n=41 Participants
10.5 units on a scale
STANDARD_DEVIATION 7.1 • n=35 Participants
ABC-Inappropriate Speech
7.0 units on a scale
STANDARD_DEVIATION 3.4 • n=39 Participants
5.8 units on a scale
STANDARD_DEVIATION 2.8 • n=41 Participants
6.4 units on a scale
STANDARD_DEVIATION 3.2 • n=35 Participants

PRIMARY outcome

Timeframe: Baseline, 6 weeks (3 week value to be collected)

The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The hyperactivity subscale is comprised of 16 items. The outcome measure is the change from baseline to 6 weeks. The total score ranges from 0 to 48.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Change in Aberrant Behavior Checklist - Hyperactivity Subscale (ABC-H) Score
-5.3 units on a scale
Standard Deviation 7.2
-3.4 units on a scale
Standard Deviation 7.5

SECONDARY outcome

Timeframe: Baseline, Week 6

The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The lethargy subscale is comprised of 16 items. The outcome measure is the change from baseline to six weeks in the scale. Total score ranges from 0 to 48.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Change in Aberrant Behavior Checklist - Lethargy Subscale Score
-2.1 units on a scale
Standard Deviation 4.2
0.1 units on a scale
Standard Deviation 2.6

SECONDARY outcome

Timeframe: Baseline, Week 6

The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The stereotypy subscale is comprised of 7 items. The outcome measure is the change from baseline to six weeks in the scale. Total score ranges from 0 to 21.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Change in Aberrant Behavior Checklist - Stereotypy Subscale Score
-2.0 units on a scale
Standard Deviation 3.7
-0.5 units on a scale
Standard Deviation 2.6

SECONDARY outcome

Timeframe: Baseline, Week 6

The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The irritability subscale is comprised of 15 items. The outcome measure is the change from baseline to six weeks in the scale. Total score ranges from 0 to 45.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Aberrant Behavior Checklist - Irritability Subscale Score
-2.0 units on a scale
Standard Deviation 6.9
-2.1 units on a scale
Standard Deviation 4.4

SECONDARY outcome

Timeframe: Baseline, Week 6

The Aberrant Behavior Checklist (ABC) is a 58-item survey. Items are rated on a 4-point scale from "0=no problem" to "3=major problem." Higher scores indicate greater severity. Scores can be computed for five subscales: hyperactivity, lethargy, stereotypical behavior, irritability, and inappropriate speech. The inappropriate speech subscale is comprised of 4 items. The outcome measure is the change from baseline to six weeks in the scale. Total score ranges from 0 to 12.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Aberrant Behavior Checklist - Inappropriate Speech Subscale Score
-0.6 units on a scale
Standard Deviation 2.7
-0.9 units on a scale
Standard Deviation 2.2

SECONDARY outcome

Timeframe: Baseline, Week 6

Social interaction will be assessed with the SRS. This scale examines the presence and extent of autistic social impairment and is administered by parents or teachers of children with ASD. Higher scores are indicative of greater severity. Normative data have been derived from a sample of over 1,600 children. A total Total-score of 76 or higher is considered severe and strongly associated with a clinical diagnosis of Autistic Disorder. T-scores of 66 through 75 are interpreted as indicating Moderate deficiencies in reciprocal social behavior that are clinically significant and lead to substantial interference in everyday social interactions, whereas T-scores of 60 to 65 are in the Mild range and indicate mild to moderate deficits in social interaction. T scores of 59 and below are considered to be within typical limits and generally not associated with clinically significant ASD.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Change in Social Responsiveness Scale (SRS) Score
-2.6 Units on a scale
Standard Deviation 8.3
-6.1 Units on a scale
Standard Deviation 7.8

SECONDARY outcome

Timeframe: Baseline, Week 6

Measures the clinical impression of improvement on a 7-point Likert scale (ranging from 1 - very much improved - to 7 - very much worse) is a commonly used measure of overall improvement in intervention studies of children with ASD. This tool will be completed by the parent and caregiver, and is therefore considered a modified version of the instrument, which is normally completed by a clinician. This is considered an exploratory analysis of this outcome tool since it is being used in a non-standard fashion. The number of participants who "responded" in each group is the number where the parents reported that their child was improved, much improved, or very much improved.

Outcome measures

Outcome measures
Measure
Omega-3
n=29 Participants
Participants randomized to omega-3
Placebo
n=28 Participants
Participants randomized to placebo
Change in Clinical Global Impression - Improvement (CGI-I) Score
12 # parents reporting improvement
10 # parents reporting improvement

Adverse Events

Omega-3

Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths

Placebo

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Omega-3
n=29 participants at risk
Participants randomized to omega-3
Placebo
n=28 participants at risk
Participants randomized to placebo
Respiratory, thoracic and mediastinal disorders
Asthma Flare
0.00%
0/29 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
3.6%
1/28 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Respiratory, thoracic and mediastinal disorders
Croup
3.4%
1/29 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Surgical and medical procedures
Elective Tonsillectomy
3.4%
1/29 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Gastrointestinal disorders
Gastrointestinal virus
3.4%
1/29 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Psychiatric disorders
Increased self-stimulatory behavior
3.4%
1/29 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Psychiatric disorders
Increased tantrums
6.9%
2/29 • Number of events 2 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/29 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
3.6%
1/28 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Vascular disorders
Nosebleed
3.4%
1/29 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Eye disorders
Conjunctivitis
0.00%
0/29 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
3.6%
1/28 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Respiratory, thoracic and mediastinal disorders
Pneumonia
0.00%
0/29 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
3.6%
1/28 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Skin and subcutaneous tissue disorders
rash
3.4%
1/29 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Infections and infestations
sinus infection
0.00%
0/29 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
3.6%
1/28 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Respiratory, thoracic and mediastinal disorders
Viral upper respiratory infection
0.00%
0/29 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
3.6%
1/28 • Number of events 1 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
Gastrointestinal disorders
vomitting
6.9%
2/29 • Number of events 2 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.
0.00%
0/28 • 6 weeks
* Families advised at start of study to contact study coordinator if child experiences a new health problem. * Families sent weekly e-mail which includes form asking about new health problems. If "yes", study doctor contacted and reviews form and contacts participant to obtain additional info and determine if further medical evaluation/treatment required. AE form questions are standard questions on FDA serious adverse event (SAE) forms.

Additional Information

Stephen Bent

University of California, San Francisco

Phone: 415-221-4810

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place